Sobi publishes Report for the Second Quarter 2013
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
second quarter 2013. Revenues for the quarter totalled SEK 520 M (481), an
increase of 8 percent. All segments of the commercial portfolio contributed to
the positive top line results in the quarter, and the pipeline programs reached
several important milestones. The company reconfirmed its outlook for the year.
Business Highlights
* Received US Food and Drug Administration (FDA) approval to manufacture drug
substance for Kineret®
* Biogen Idec and Sobi presented further data from the phase 3 studies of
their long-lasting haemophilia factor candidates
* Completed enrolment for the Kiobrina® LAIF (Lipase Added to Infant Feeding)
phase 3 study
Financial Highlights
* Total revenues increased by 8 percent to SEK 520.2 M (480.7)
* Gross margin was 61 percent (51) for the quarter
* Ended the quarter with a cash position of SEK 438.1 M
* Outlook for 2013 remains unchanged
"We continued to make progress across our business in the second quarter.
Revenue for the overall portfolio grew by 8 percent compared to last year, with
Kineret, Orfadin® and Partner Products showing strong performance at the mid-
point in the year. The gross margin is evolving as expected and we are making
solid progress financially with improved profitability and a stable cash
position," said Geoffrey McDonough, CEO and President. "In addition, our
pipeline posted several significant events including the FDA approval for the
manufacture of drug substance for Kineret at Boehringer Ingelheim's site in
Vienna and the release of additional data from the phase 3 trials of our long-
lasting recombinant clotting factors for Haemophilia."
---
Sobi's report for the second quarter 2013 can be found on
http://www.sobi.com/Investors--Media/Reports/
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late-stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(? 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on July 18, 2013, at 8:00 CET
Sobi Report for the Second Quarter 2013:
http://hugin.info/134557/R/1717193/570890.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1717193]
Unternehmensinformation / Kurzprofil:
Datum: 18.07.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 279548
Anzahl Zeichen: 4245
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi publishes Report for the Second Quarter 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
